Skip to main content
. Author manuscript; available in PMC: 2024 Nov 1.
Published in final edited form as: Clin Pharmacol Ther. 2023 Sep 13;114(5):994–1001. doi: 10.1002/cpt.3030

Table 1:

Published reports of novel oligonucleotides to treat individual patients

Drug Name Specificity Target and Condition Reference
Milasen Variant-specific CLN7 Batten disease 4
Jacifusen* Gene-specific FUS amyotrophic lateral sclerosis 5
Afinersen* Gene-specific C9ORF72 amyotrophic lateral sclerosis 6
Atipeksen Variant-specific ATM ataxia telangectasia 7
*

A single patient was treated but the mechanism is not specific to that individual.